Today before the opening bell, VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, announced it has commenced blood sample analysis for its largest clinical study to date, in collaboration with Hvidovre … Continue reading →

VolitionRx, an ambitious life sciences company, wants to make non-invasive blood tests for cancer as commonplace and easy to use as current blood tests for diabetes and high cholesterol. With only one blood test for cancer—the Prostate-Specific Antigen test for … Continue reading →

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, this morning told investors that the company presented at the 2nd annual MicroCapClub Invitational. The company’s presentation can be accessed at the following … Continue reading →

Today before the opening bell, MissionIR announced that a new audio interview with VolitionRx, Ltd. (OTCQB: VNRX) President and CEO Cameron Reynolds had been published online. The entirety of the interview can be found at: http://vnrx.missionir.com/interview.html. VolitionRx is a publicly … Continue reading →

VolitionRx is developing two types of non-invasive cancer diagnostic tests based on its patented Nucleosomics® technology. The company’s overarching goal is to bring to market its cancer blood tests and revolutionize cancer diagnosis. While VolitionRx’s current focus is on the … Continue reading →

Today, shortly after the opening bell, VolitionRx announced that it has engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and … Continue reading →